Sickle Cell Disease Gene Therapy

A LucidScope AI Visibility and Perception Analysis

How leading AI search models perceive, rank, and position SCD gene therapies

Scope 4 AI models · 12 model runs · 4 therapies **Reporting period** through June 2026

AT A GLANCE

35%	4	12	72
CASGEVY SHARE OF VOICE	AI MODELS COMPARED	MODEL RUNS ANALYSED	SAFETY EMPHASIS SCORE (TOP CONCERN)

Table Of Contents

Executive summary

This analysis assessed how **four AI models** perceive and position **four sickle cell disease gene therapies** across **12 model runs**, focusing on visibility, efficacy, safety, market sentiment, and source behavior.

Key Findings

- **Casgevy emerged as the strongest overall therapy**, with **35% share of voice** versus **30% for Lyfgenia**, **18% for Beam-101 / risto-cel**, and **16% for CS-206**. Its leadership is mainly driven by **approval status**, **mature clinical evidence**, and stronger efficacy positioning.



Share of voice across 12 model runs

- **Safety was the dominant theme**, with a **patient safety emphasis score of 72**, far above efficacy and market sentiment. AI models repeatedly focused on **conditioning burden**, cytopenias, infections, fertility concerns, and **long-term monitoring**.
- **Beam-101 emerged as the leading investigational challenger**, supported by positive efficacy narratives and strong visibility from company-controlled sources.
- **Lyfgenia remained the closest approved competitor**, but its AI identity is strongly shaped by its **boxed warning for hematologic malignancy**.
- **AI outputs varied depending on retrieval behavior and source selection**, creating differences in therapy ranking, evidence interpretation, and competitor visibility.

Strategic Implications

- **Casgevy leads AI positioning**, but class-wide **safety narratives may dilute its efficacy advantage** if they are not clearly contextualised.
- **Beam-101** shows how **future-oriented narratives** can gain visibility **before regulatory approval**, especially when investor and company sources are highly retrievable.
- **Safety is now the primary lens** through which AI models evaluate SCD gene therapies, meaning efficacy leadership alone may not be enough to protect perception.
- **Source quality and availability materially influence AI-generated conclusions.** Therapies with clearer, more accessible, and more authoritative evidence may be more favourably represented in AI outputs.

Recommended Actions

- Strengthen visibility of **authoritative clinical and regulatory evidence**, especially from trusted medical, regulatory, and peer-reviewed sources.
- Create clearer content separating **product-specific risks** from broader **treatment-class burden**, including conditioning-related risks and long-term follow-up requirements.
- Expand **patient-experience content** to balance safety-focused narratives with real-world treatment journey and benefit stories.
- Monitor **high-impact prompts**, **competitor positioning**, and **source visibility** over time to identify perception risks before they become embedded in AI-generated answers.

Detailed Findings

Clinical Efficacy

CLINICAL EFFICACY Prompt: *"Analyze the clinical efficacy of all drugs."*

Finding #1: Casgevy consistently leads on clinical evidence maturity

Clinical establishment was the clearest point of model agreement.

- **Casgevy was consistently positioned as the most clinically established therapy** across all four models, supported by FDA approval and pivotal data in both SCD and TDT.
- **GPT-5.5** provided the **clearest efficacy hierarchy**: Casgevy first, Lyfgenia second, Beam-101 / risto-cel third, and CS-206 fourth.
- **Ranking drivers** included clinical maturity, endpoint rigour, treated-patient numbers, and duration of follow-up.

Finding #2: Lyfgenia is the closest approved comparator; Beam-101 leads the investigational set

Comparability was weaker beyond Casgevy.

- **Lyfgenia was recognised as strong but harder to compare directly** because its endpoint is VOE-CR / severe VOE-CR over months six to eighteen, not Casgevy's VF12 / HF12 framework.
- **Beam-101 / risto-cel was framed as the leading investigational challenger** with growing visibility in the model outputs.
- **CS-206 was treated as biologically plausible but very early stage,** with evidence still essentially limited to n=1.

EFFICACY SNAPSHOT

Therapy	Status	Key efficacy data (as cited by GPT-5.5)	Maturity
Casgevy	FDA-approved	SCD: 29/31 (93.5%) VF12; 30/30 HF12. TDT: 32/35 (91.4%) TI12	**Most mature**
Lyfgenia	FDA-approved	28/32 (88%) VOE-CR; 30/32 (94%) severe VOE-CR (months 6–18)	Mature; boxed warning
Beam-101 / risto-cel	Investigational	31 treated; HbF >60%, HbS <40%; no severe VOCs post-engraftment; 0.3–20.4 mo follow-up	**Emerging leader**
CS-206	Investigational (n=1)	>15 mo VOC-free post-engraftment; HbF:HbS ~6:4	Earliest stage

Finding #3: Models differ in how they assess evidence maturity and emerging therapies

Model behavior differed meaningfully across the audit, with each model shaping the competitive narrative in a slightly different way:

- **GPT-5.5:** Balanced and evidence-ranked.
- **Claude Sonnet 4.6:** More expansive and gave greater visibility to Beam-101 / risto-cel.
- **Gemini-3.5-Flash:** More promotional, describing base-editing therapies as "functional cures" and using language such as "near-flawless clinical indicators," which overstates what single-arm early-phase data can support.
- **Sonar:** Most conservative and stated it could not assess CS-206 from the sources it found.

Finding #4: Sentiment varies by evidence maturity and risk profile

Overall efficacy sentiment was positive, with Casgevy receiving the strongest support, Lyfgenia viewed positively but with comparability caveats, Beam-101 / risto-cel generating optimism despite immature data, and CS-206 remaining uncertain due to limited evidence.

Patient Safety & Side Effects

PATIENT SAFETY & SIDE EFFECTS Prompt: "Analyze the primary patient safety concerns and side effects for all drugs."

Finding #5: Safety is framed around transplant-like burden and long-term monitoring

The central narrative is that these therapies are **not perceived as simple "one-time cures."** Instead, they are seen as **transplant-like autologous cell therapies** with a significant treatment burden, including mobilisation, manufacturing, myeloablative conditioning, cytopenia management, infection monitoring, fertility counselling, and long-term follow-up.

Findings #6-#8: Each product carries a distinct safety identity

Therapy	Defining safety signal	Selected AE rates (GPT-5.5)
Casgevy	Conditioning burden; uncertain off-target CRISPR editing; delayed platelet engraftment	SAR 45%; gr 3/4 mucositis 86%; febrile neutropenia 48%; ↓appetite 41%; gr 3/4 neutropenia / thrombocytopenia 100%
Lyfgenia	**Boxed warning — hematologic malignancy / insertional oncogenesis; up to 15-yr monitoring**	SAE 73%; gr ≥3 stomatitis 71%; thrombocytopenia 69%; neutropenia 60%; febrile neutropenia 44%; anemia 33%
Beam-101	Promising but immature; profile broadly consistent with conditioning	31/31 ≥1 AE; 87% gr ≥3 AE; 39% SAE; one death (idiopathic pneumonia syndrome)
CS-206	Too early to characterise; "no product-related AEs" caveated as single-patient	Single-patient evidence only

Single-arm, early-phase and cross-trial figures are not directly comparable; rates are shown per product as cited, not as a head-to-head.

Finding #9: Models differ in safety rigor, source use, and evidence standards

Model behavior also differed in the safety analysis, especially in how each model handled evidence quality and uncertainty:

- **GPT-5.5:** Gave the most granular percentages, but its safety run had no structured citation array despite inline URLs.
- **Gemini:** Generalized the comparison and leaned on base-editing **"precision"** as a presumed safety advantage.
- **Claude:** Was more comparative and risk-ranked.
- **Sonar:** Again failed to verify CS-206.

Finding #10: Safety is the dominant negative theme across all models

Patient Safety was the dominant theme, carrying an emphasis score of 72, far above Efficacy (21.6) and Market Sentiment (22), indicating that safety concerns account for the largest share of discussion across the dataset.



Topic emphasis scores — safety dominates the dataset

STRATEGIC READ

Safety is the single biggest force shaping AI perception of this class. Even Casgevy, which carries no malignancy signal, is bundled into a high-burden, transplant-like class narrative that can dilute its efficacy leadership.

Market Sentiment & Patient Feedback

MARKET SENTIMENT & PATIENT FEEDBACK Prompt: "Summarize the general market sentiment and patient feedback for all drugs."

Finding #11: Sentiment is positive on efficacy but constrained by adoption barriers

The shared story is **clinical enthusiasm but slow commercial adoption**. Models described Casgevy and Lyfgenia as effective yet constrained by treatment-center capacity, cell collection, manufacturing timelines, payer access, conditioning chemotherapy, hospitalisation, fertility concerns, and patient hesitation.

Findings #12-#15: Commercial signals diverge sharply across the four assets

Therapy	Commercial signal (as surfaced by models)
Casgevy	$43M Q1 2026 revenue; >500 globally initiating the treatment journey; ~90% of U.S. patients with reimbursed access by YE 2025; but 64 SCD/TDT infusions in 2025 and 147 first cell collections — strong, improving, throughput-limited.
Lyfgenia	>100 U.S. patients treated in 2025; >150 first cell collections; manufacturing expansion. Commercially fragile but recovering after the bluebird bio → Genetix Biotherapeutics transition (Sept 2025).
Beam-101	Most positively framed investigational asset: possible BLA as early as YE 2026, one-cycle collection, rapid manufacturing, strong BEACON data (NEJM).
CS-206	Scientifically interesting but commercially irrelevant in the U.S.: June 2026 single-patient CorrectSequence report; Sonar could not retrieve it.

Finding 16: Patient feedback remains sparse and uneven

Patient feedback visibility varied significantly across therapies

- **Casgevy** had limited fresh first-person feedback in the last six months, while
- **Lyfgenia** had the strongest patient-story footprint through sources such as Children's DMC, UCLA, and Reddit.
- **Beam-101** feedback was largely inferred from trial outcomes rather than direct testimonials
- **CS-206** remained represented primarily through developer and news-reported updates.

Per-Model Behavior

How each model approached the task, what it favored, the sources it leaned on, and where it introduced risk.

Model	Behavior	Brand / competitor tendency	Source quality & recency	Errors / risks
GPT-5.5	Most clinically disciplined. Uses tables, endpoint definitions, and explicit data-maturity ranking.	Favours Casgevy on efficacy confidence; positions Beam-101 strongly but clearly as investigational.	Strong use of FDA, ClinicalTrials.gov, DailyMed / label sources, company releases, NEJM-style references.	Safety run lacks a structured citation array despite inline URLs; inconsistent CS-206 identifier handling.
Gemini-3.5-Flash	More promotional and technology-forward. Broader claims, stronger language.	Over-favours next-generation base-editing narratives, especially Beam-101 and CS-206.	Market run cited; efficacy/safety runs lack structured arrays. Uses lower-authority domains (PackGene, YouTube, Spherix).	Over-claims "functional cure" and "safer" base-editing before large comparative safety datasets exist.
Claude Sonnet 4.6	Most verbose and source-heavy. Analyst-style synthesis, with some process leakage ("Now I have enough information").	Strongly positive on Casgevy commercial acceleration and Beam-101 excitement; more negative on Lyfgenia safety.	Highest citation volume (114 entries) but mixed quality; heavy use of investor, finance, and patient-news sources.	Cites Wikipedia despite excluded domains (incl. an irrelevant listeriosis page); uses OpenPR and stock commentary.
Sonar	Shortest and most skeptical. Good at caveating maturity and access burden.	Favours approved therapies by evidentiary maturity; under-recognises CS-206.	38 citations; some reasonable sources but also reliance on secondary summaries.	Repeatedly says it cannot verify CS-206, although CS-206 references exist elsewhere in the data.

Source and Citation Analysis

The source footprint does not mirror share of voice. Although Casgevy leads overall share of voice, Beam's investor domain dominates the source landscape by a wide margin, creating a strategically important mismatch between visibility and source influence.



Most-cited domains across the export (appearance counts

Finding #17: Authoritative clinical and regulatory sources are present

High-quality clinical and regulatory sources were consistently represented. FDA, DailyMed, ClinicalTrials.gov, NEJM, PMC / PubMed / NCBI, ASH Publications, and the EHA library all appear, which are appropriate sources for efficacy, label safety, and trial-stage comparison.

Finding #18: Company-controlled and lower-authority sources create framing risk

Models frequently used company-controlled and investor domains (investors.beamtx.com, news.vrtx.com, ir.crisprtx.com, lyfgenia.com, casgevyhcp.com, beamtx.com). That is not inherently wrong, but it means **AI outputs may inherit sponsor framing**. Lower-authority sources also appeared, including OpenPR, Seeking Alpha, Simply Wall St, Yahoo Finance, StockTitan, Reddit, and YouTube.

Finding #19: Source overlap is low across models

AI answer composition is source-fragile. Models did not strongly agree on sources. **Only investors.beamtx.com, biospace.com, and sicklecellanemianews.com were cited across all four.** This low overlap shows that AI answer composition is source-fragile: the same prompt can generate different evidentiary bases depending on retrieval behavior.

Strategic Implications: Risks, Opportunities and Recommended Actions per Therapy

CASGEVY: The validated leader, Defending the position

CURRENT AI PERCEPTION OF CASGEVY

Casgevy leads the current AI narrative but faces several vulnerabilities.

- **Leads the efficacy hierarchy and captures 35% share of voice.**
- **The source landscape disproportionately favours Beam**, despite Casgevy's leadership in overall visibility.
- **The class-wide safety narrative weighs on perception**, regardless of efficacy leadership.
- **Patient-story visibility trails Lyfgenia**, limiting real-world narrative strength.

Key Risks

1. **Wins the efficacy hierarchy, not the citation hierarchy.** Casgevy leads share of voice, but Beam has stronger source-map influence. Beam's investor site dominates the source map, giving Beam-101 a disproportionate chance to shape "next best therapy" narratives.

2. **Safety framing can dilute efficacy leadership.** Casgevy is pulled into a high-burden class narrative. Repeated emphasis on busulfan conditioning, cytopenias, mucositis, infection, fertility, and long-term genomic uncertainty reinforces treatment-burden concerns, even without Lyfgenia's malignancy identity.

3. **Beam-101 is becoming the main AI-visible future threat.** Beam-101 is increasingly positioned as a best-in-class or next-wave therapy. Left unbalanced, AI models may present it as the "cleaner future option" before approval or long-term safety confirmation.

4. **Patient-story visibility is weaker than Lyfgenia's.** Lyfgenia benefits from stronger patient-story visibility. Models retrieve what is easiest to find, and Lyfgenia currently has more visible patient-story content.

5. **CS-206 creates naming and retrieval noise.** Early-asset visibility remains unstable. Some models confuse CS-206 with CS-101, showing how limited visibility can distort competitor mapping and asset perception.

Key Opportunities

1. **Strengthen Casgevy's evidence visibility and narrative control.** Build a high-authority Casgevy evidence hub covering SCD and TDT separately, including VF12, HF12, TI12, paediatric 5–11 updates, follow-up duration, and treatment-process caveats.

2. **Improve endpoint comparability and interpretation.** Publish a Casgevy vs Lyfgenia endpoint explainer showing why VF12, HF12, VOE-CR, severe VOE-CR, and TI12 should not be compared simplistically.

3. **Separate product-specific risk from treatment burden.** Create a safety page that distinguishes conditioning-related risks from product-specific genomic risks, with clear monitoring, fertility, engraftment, and follow-up content.

4. **Expand sourceable patient-experience content.** Increase first-person U.S. stories that discuss both disease-control benefit and the treatment journey honestly.

5. **Raise visibility of Vertex / CRISPR access progress.** Make access, manufacturing, treatment-center activation, and pediatric expansion easier for models to retrieve than secondary commentary.

Recommended Actions

1. **Target the domains AI models already trust.** FDA, DailyMed, ClinicalTrials.gov, PubMed / PMC, NEJM, ASH, EHA, major academic centers, CMS / Medicaid access sources, and reputable patient-advocacy channels

2. **Counter the Beam-101 story with precision, not defensiveness.** Emphasise approved status, dual-indication data, regulatory-reviewed endpoints, follow-up maturity, and that Beam-101 still shares the ex vivo autologous / conditioning burden.

3. **Close source gaps on market access and real-world adoption.** Provide clean, frequently updated facts on access, patient starts, cell collections, infusions, center capacity, and reimbursement.

4. **Fix prompt-level visibility issues.** Monitor exact prompts such as "best sickle cell gene therapy," "Casgevy vs Lyfgenia," "Casgevy side effects," and "newer safer alternatives to Casgevy."

5. **Audit retrieval controls.** Wikipedia leakage despite excluded domains indicates the platform should enforce exact and subdomain-level blocking, then flag irrelevant citations automatically.

LYFGENIA: The boxed-warning competitor, Reframing the narrative

CURRENT AI PERCEPTION OF LYFGENIA

Lyfgenia is the closest approved competitor, but safety defines its AI identity.

- **Position:** Lyfgenia holds 30% share of voice.
- **Efficacy:** Models recognize meaningful efficacy, with 28/32 patients achieving VOE-CR and 30/32 achieving severe VOE-CR.
- **Risk overhang:** Its AI identity remains dominated by the boxed warning for hematologic malignancy and long-term monitoring, even as Genetix-reported commercial progress improves sentiment.

Key Risks

1. **Safety identity may overpower efficacy.** Models repeatedly frame Lyfgenia around hematologic malignancy, insertional oncogenesis, 15-year monitoring, delayed platelet engraftment, and busulfan / HSCT burden.

2. **Endpoint comparability risk.** Casgevy benefits from cleaner AI-readable VF12 / HF12 framing, while Lyfgenia's VOE-CR endpoints over months 6–18 are harder for models to compare directly.

3. **Corporate-transition noise.** The bluebird bio → Genetix Biotherapeutics transition may confuse AI retrieval and attribution unless source materials are consistently updated.

4. **Patient feedback is positive but burdened.** Lyfgenia has more visible patient stories than Casgevy, but those stories also describe chemotherapy, hospitalisation, recovery burden, residual symptoms, and ongoing monitoring.

Key Opportunities

1. **Reframe beyond the boxed-warning narrative.** Position Lyfgenia as the most commercially demonstrated SCD gene therapy competitor — not just the "boxed warning" product.

2. **Clarify endpoint comparability versus Casgevy.** Build sourceable comparisons explaining VOE-CR vs VF12, why cross-trial comparison is limited, and where Lyfgenia's longer follow-up is relevant.

3. **Strengthen medically reviewed safety content.** Increase high-quality, medically reviewed content on risk mitigation, monitoring, and patient selection.

4. **Use patient stories to balance benefit and burden.** Increase high-quality, medically reviewed content on risk mitigation, monitoring, and patient selection.

Recommended Actions

1. **Consolidate evidence under updated Genetix domains.** Publish an updated Lyfgenia evidence page that consolidates efficacy, safety, monitoring, manufacturing, and real-world treatment numbers.

2. **Standardise product naming across authoritative sources.** Ensure FDA label, DailyMed, Lyfgenia HCP, Genetix, and major treatment-center content all use consistent naming.

3. **Create AI-readable FAQs on safety and comparison.** Address "Does Lyfgenia cause cancer?", "How does Lyfgenia compare with Casgevy?", and "What does long-term monitoring involve?

4. **Increase peer-reviewed and congress-based visibility.** Seed peer-reviewed / congress follow-up analyses to dilute reliance on secondary news, anecdotes, and financial sources.

BEAM-101 / RISTO-CEL: The emerging challenger. Building credible differentiation

CURRENT AI PERCEPTION OF BEAM-101 / RISTO-CEL

Beam-101 has lower current visibility but the strongest future-threat narrative.

- **Share of voice:** Beam-101 has lower share of voice than approved products at 18%.
- **Source influence:** investors.beamtx.com is the single most-cited domain overall, with 69 appearances.
- **AI perception:** Models describe Beam-101 as the leading investigational challenger.
- **Evidence cited:** Models highlight 31 treated patients, HbF >60%, HbS <40%, no severe VOCs after engraftment, one-cycle collection, and possible BLA as early as YE 2026.

Key Risks

1. **Models may overstate pre-approval potential.** Gemini and Claude in particular drift from "promising investigational profile" toward "potential best-in-class" before regulatory review, longer follow-up, and broader safety characterisation.

2. **Visibility relies heavily on company-controlled sources.** Beam's investor site dominates the citation environment — helpful for visibility, but a vulnerability if users or models discount company-controlled sources.

3. **Treatment burden may be underappreciated.** Outputs highlight one-cycle collection and fast manufacturing but may understate that risto-cel still involves ex vivo autologous therapy, myeloablation, transplant-center burden, infertility risk, cytopenias, and long-term follow-up.

4. **Safety conclusions rest on limited follow-up.** GPT-5.5 cited 87% grade ≥3 AEs, 39% SAEs, and one death from idiopathic pneumonia syndrome in interim data, even where models frame the profile as conditioning-consistent.

Key Opportunities

1. **Establish the leading next-generation candidate position. Beam** can become the default "next-generation SCD gene therapy" if it maintains source visibility across NEJM, ClinicalTrials.gov, EHA / ASH, investor releases, and high-quality medical media.

2. **Differentiate on operations and workflow.** The strongest angle is not only efficacy but operational differentiation: one collection cycle, shorter release timelines, and smoother treatment-center workflow.

3. **Balance the base-editing narrative with evidence.** AI systems are receptive to "base editing without double-strand breaks," but this should be anchored by data, not purely mechanistic claims.

Recommended Actions

1. **Expand peer-reviewed and congress evidence.** Continue building sourceable, peer-reviewed evidence beyond investor communications, particularly as follow-up data mature.
2. **Publish workflow comparisons versus Casgevy and Lyfgenia.** Highlight differences in collection, manufacturing, conditioning, and treatment workflows using objective, sourceable comparisons.
3. **Anchor differentiation claims to measurable data.** Avoid "best-in-class" language before approval and instead position Beam-101 as a potentially differentiated investigational therapy supported by measurable evidence.
4. **Optimise for high-impact AI comparison prompts.** Develop dedicated content for queries such as "Beam-101 vs Casgevy", "risto-cel efficacy", "base editing sickle cell therapy", and "next sickle cell gene therapy after Casgevy".

CS-206: The early-stage watchlist asset, Fixing the footprint

CURRENT AI PERCEPTION OF CS-206

CS-206 has meaningful visibility, but its AI identity remains fragile.

- **Share of voice:** CS-206 accounts for 16% of overall share of voice.
- **Visibility risk:** Its presence depends heavily on whether models retrieve the June 2026 CorrectSequence announcement.
- **AI perception:** GPT-5.5 describes CS-206 as biologically plausible but still essentially n=1.
- **Evidence and naming risk:** While models cite a first patient who remained VOC-free for more than 15 months after engraftment, Sonar repeatedly fails to verify the asset and raises naming confusion, creating a material perception challenge for an early-stage programme.

Key Risks

1. **Evidence immaturity dominates the narrative.** Models correctly treat CS-206 as early Phase 1 / single-patient evidence, not a commercial-stage therapy.

2. **U.S. relevance is weak.** The market-sentiment prompt frames CS-206 as scientifically interesting but with minimal U.S. commercial relevance.

3. **Retrieval failure and naming confusion are material. Sonar's** inability to verify CS-206 shows the asset's digital footprint is not robust across model search systems.

4. **Company-reported data may be discounted.** The key positive claim comes from a press release / secondary summary rather than a peer-reviewed dataset.

Key Opportunities

1. **Own an early high-precision watchlist position.** CS-206 can hold a credible high-precision base-editing watchlist position if naming, mechanism, trial registry, and clinical-update sources are made consistent.

2. **Frame the n=1 result honestly.** The single-patient result is strong enough to generate curiosity, but it should be presented as an early signal rather than proof of efficacy.

3. **Treat the feedback gap as not yet critical.** The lack of patient-reported feedback is not currently a major weakness, but it may become one as competing therapies accumulate testimonials.

Recommended Actions

1. **Standardise naming across all public materials.** Align CS-206, CorrectSequence / Correctseq, mechanism, sponsor, trial ID, and geography.

2. **Publish a retrievable clinical-development page.** Create a simple authoritative page linking the trial registry, mechanism, eligibility, endpoints, and public updates.

3. **Convert the single-patient update into a precise evidence narrative.** Include patient baseline, timing from infusion and engraftment, VOC-free duration, anemia status, HbF / HbS evolution, engraftment, and adverse events.

4. **Prioritise peer-reviewed abstracts and congress presentations.** Until CS-206 has ASH, EHA, or journal visibility, models will keep treating it as speculative.

5. **Monitor prompts where retrieval may fail.** Track "CS-206 sickle cell," "CorrectSequence CS-206," "Correctseq base editing sickle cell," and "new base editing therapy for sickle cell disease."

About LucidQuest

Strategic Insights and Strategy Development is our focus.
We use evidence-based insights to solve key business issues our Pharma, Biotech and Healthcare clients are facing and to provide reliable investment analyses and recommendations for our investor partners.

COMPETITIVE STRATEGY AND INTELLIGENCE

DIGITAL HEALTH, ARTIFICIAL INTELLIGENCE AND IoE

GENE & CELL THERAPY

VACCINES & INFECTIOUS DISEASES

INVESTMENT INSIGHTS